Contamac Ltd. and Brien Holden Vision Institute Enter License Agreement for Myopia Control
Publish Date: 23 January 2015
Contamac Ltd., a leader in the development of specialist polymers and a major global provider of biocompatible materials for implantable and medical applications to the ophthalmic industry, and Brien Holden Vision Institute, whose mission is to develop new solutions for vision care and eliminate vision impairment and avoidable blindness, have entered into a multi-year license, which enables Contamac Ltd to commercialize and distribute customized Silicone Hydrogel and GP contact lens products based on utilizing Background Intellectual Property on myopia control from the Brien Holden Vision Institute.
“We hear time and time again that Eye Care Professionals are regularly practicing myopia control with contact lenses in their patients, with recent reports suggesting that this number could be as high as 24%, and, most importantly, the interest within the specialty contact lens industry is growing ever so rapidly,” said Martin Dalsing, Contamac’s Director of Global Strategy and Business Development. “Making available these specialized custom lens parameters and designs to the Eye Care Professional through our laboratory network will be crucial for today’s modern specialty contact lens practice”.
“This is an important step in making effective myopia control technologies available to reduce the rate of progress of myopia and the risk of permanent vision impairment associated with high levels of myopia later in life,” said Professor Brien Holden, CEO, Brien Holden Vision Institute. “Myopic macular degeneration is now the leading cause of new blindness in some locations in Asia, and with the number of myopes estimated to reach 2.2 billion by 2020 and the number of high myopes increasing rapidly, there is an urgent need for better interventions.” The Brien Holden Vision Institute believes that licensing its Background Intellectual Property to companies who are interested in myopia control is an excellent way to see these products in action for the benefit of myopes throughout the world. "Contamac is the first specialist company to take up such a license and develop their own designs. We expect there will be many more in the different contact lens fields.”
Under the license, Contamac Ltd. will begin to commercialize specialized contact lenses designed to reduce the rate of myopia progression in children by sub-licensing the Contamac designs to key strategic partners within its existing customer base throughout the world, commencing in May 2015. The technology licensed by Brien Holden Vision Institute includes numerous U.S. and foreign patents.
Currently, a myopia control indication for use submission to the U.S. FDA is to be completed in early 2017 as part of Contamac Ltd’s commercialization plan.